Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11270767 | 0.92 | HRH3 (0.40) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL646005 | 0.88 | KDM4E (0.50) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL4526651 | 0.87 | KEAP1 (0.52) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL7226171 | 0.83 | USP2 (0.44) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL5419101 | 0.82 | KEAP1 (0.47) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL27160143 | 0.80 | ALDH1A1 (0.43) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL17996882 | 0.79 | HRH3 (0.38) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL235080 | 0.77 | KDM4E (0.65) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL4042388 | 0.76 | HRH3 (0.42) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL11333121 | 0.75 | TDP1 (0.41) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892534-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2892534-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| WO-2014039714-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | KDM4E 1125/4885SMN1; SMN2 2565/4885KEAP1 2938/4885 |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | KDM4E 1125/4885SMN1; SMN2 2565/4885KEAP1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.